Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Merck names Frazier president: Merck, in an expected move, appoints the current head of its Global Human Health business, Ken Frazier, as president of the firm. Frazier moves to the spot after three years in the Global Human Health post and as Merck's general counsel for eight years prior to that, the firm said April 28. Adam Schechter, current U.S. head for Global Human Health, will succeed Frazier as global president. Current Merck President Dick Clark will remain as CEO and chairman; both Schecter and Frazier are seen as potential successors to Clark. Merck in February appointed former Johnson & Johnson executive Bridgette Heller as executive VP and president of its consumer health care division. Whitehouse Station, N.J.-based Merck acquired the division as part of its November 2009 merger with Schering-Plough (1"The Tan Sheet" Feb. 22, 2010)

You may also be interested in...



Merck's Frazier Promoted To CEO To Drive Post-Schering Success

Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.

Merck's Frazier Promoted To CEO To Drive Post-Schering Success

Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.

Merck's Frazier Promoted To CEO To Drive Post-Schering Success

Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel